The Conversation (0)
PharmaTimes reports that KKR has agreed to take over ReSearch Pharmaceutical Services (RPS) from its private-equity owner, Warburg Pincus.
PharmaTimes reports that KKR has agreed to take over ReSearch Pharmaceutical Services (RPS) from its private-equity owner, Warburg Pincus. No financial details of the offer were disclosed.
As reported in the market news:
The transaction will bring together “two highly complementary companies with PRA as a leader in traditional programmatic outsourced clinical development and RPS as a pioneer of the innovative Embedded clinical development model,” commented Jim Momtazee, head of KKR’s Health Care investing team.